Gold nanoparticle-based colorimetric assay for cancer diagnosis. 2010

Jeong-Hun Kang, and Yoji Asami, and Masaharu Murata, and Hirotaro Kitazaki, and Noriaki Sadanaga, and Eriko Tokunaga, and Satoko Shiotani, and Satoko Okada, and Yoshihiko Maehara, and Takuro Niidome, and Makoto Hashizume, and Takeshi Mori, and Yoshiki Katayama
Department of Applied Chemistry, Faculty of Engineering, Kyushu University, 744 Motooka, Nishi-Ku, Fukuoka 819-0395, Japan.

A novel gold nanoparticle (GNP)-based colorimetric assay was developed for cancer diagnosis. This system is based on the noncrosslinking aggregation mechanism with a cationic protein kinase C (PKC) alpha-specific peptide substrate, which is used as a coagulant of citrate-coated GNP with anionic surface charges. The phosphorylation of peptide substrates by PKCalpha suppressed GNP aggregation, resulting in a red color, but in the case of non-phosphorylation, the color of the GNP solution changed from red to blue, indicating particle aggregation. Moreover, a correlation between the color change of the GNP dispersions and the level of activated PKCalpha was identified from experiments using cancer cell lines, or xenografted mouse cancer and normal mouse tissues. When our system was applied to human breast cancers and normal human breast tissues, cancer tissue lysates became red in color, indicating GNP dispersion, while all lysates from normal tissue turned the GNP solution blue. MALDI-TOF MS analysis and Western blotting experiment confirmed that these different results between cancer and normal tissues reflected the difference in PKCalpha activity. This study is the first report on the application of the GNP-based colorimetric assay to the diagnosis of cancer.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011493 Protein Kinase C An serine-threonine protein kinase that requires the presence of physiological concentrations of CALCIUM and membrane PHOSPHOLIPIDS. The additional presence of DIACYLGLYCEROLS markedly increases its sensitivity to both calcium and phospholipids. The sensitivity of the enzyme can also be increased by PHORBOL ESTERS and it is believed that protein kinase C is the receptor protein of tumor-promoting phorbol esters. Calcium Phospholipid-Dependent Protein Kinase,Calcium-Activated Phospholipid-Dependent Kinase,PKC Serine-Threonine Kinase,Phospholipid-Sensitive Calcium-Dependent Protein Kinase,Protein Kinase M,Calcium Activated Phospholipid Dependent Kinase,Calcium Phospholipid Dependent Protein Kinase,PKC Serine Threonine Kinase,Phospholipid Sensitive Calcium Dependent Protein Kinase,Phospholipid-Dependent Kinase, Calcium-Activated,Serine-Threonine Kinase, PKC
D003124 Colorimetry Any technique by which an unknown color is evaluated in terms of standard colors. The technique may be visual, photoelectric, or indirect by means of spectrophotometry. It is used in chemistry and physics. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
D004867 Equipment Design Methods and patterns of fabricating machines and related hardware. Design, Equipment,Device Design,Medical Device Design,Design, Medical Device,Designs, Medical Device,Device Design, Medical,Device Designs, Medical,Medical Device Designs,Design, Device,Designs, Device,Designs, Equipment,Device Designs,Equipment Designs
D006046 Gold A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D015203 Reproducibility of Results The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results. Reliability and Validity,Reliability of Result,Reproducibility Of Result,Reproducibility of Finding,Validity of Result,Validity of Results,Face Validity,Reliability (Epidemiology),Reliability of Results,Reproducibility of Findings,Test-Retest Reliability,Validity (Epidemiology),Finding Reproducibilities,Finding Reproducibility,Of Result, Reproducibility,Of Results, Reproducibility,Reliabilities, Test-Retest,Reliability, Test-Retest,Result Reliabilities,Result Reliability,Result Validities,Result Validity,Result, Reproducibility Of,Results, Reproducibility Of,Test Retest Reliability,Validity and Reliability,Validity, Face

Related Publications

Jeong-Hun Kang, and Yoji Asami, and Masaharu Murata, and Hirotaro Kitazaki, and Noriaki Sadanaga, and Eriko Tokunaga, and Satoko Shiotani, and Satoko Okada, and Yoshihiko Maehara, and Takuro Niidome, and Makoto Hashizume, and Takeshi Mori, and Yoshiki Katayama
April 2017, Analytical chemistry,
Jeong-Hun Kang, and Yoji Asami, and Masaharu Murata, and Hirotaro Kitazaki, and Noriaki Sadanaga, and Eriko Tokunaga, and Satoko Shiotani, and Satoko Okada, and Yoshihiko Maehara, and Takuro Niidome, and Makoto Hashizume, and Takeshi Mori, and Yoshiki Katayama
February 2007, Analytica chimica acta,
Jeong-Hun Kang, and Yoji Asami, and Masaharu Murata, and Hirotaro Kitazaki, and Noriaki Sadanaga, and Eriko Tokunaga, and Satoko Shiotani, and Satoko Okada, and Yoshihiko Maehara, and Takuro Niidome, and Makoto Hashizume, and Takeshi Mori, and Yoshiki Katayama
February 2008, Analytical chemistry,
Jeong-Hun Kang, and Yoji Asami, and Masaharu Murata, and Hirotaro Kitazaki, and Noriaki Sadanaga, and Eriko Tokunaga, and Satoko Shiotani, and Satoko Okada, and Yoshihiko Maehara, and Takuro Niidome, and Makoto Hashizume, and Takeshi Mori, and Yoshiki Katayama
September 2005, Chemical communications (Cambridge, England),
Jeong-Hun Kang, and Yoji Asami, and Masaharu Murata, and Hirotaro Kitazaki, and Noriaki Sadanaga, and Eriko Tokunaga, and Satoko Shiotani, and Satoko Okada, and Yoshihiko Maehara, and Takuro Niidome, and Makoto Hashizume, and Takeshi Mori, and Yoshiki Katayama
December 2017, Nanoscale,
Jeong-Hun Kang, and Yoji Asami, and Masaharu Murata, and Hirotaro Kitazaki, and Noriaki Sadanaga, and Eriko Tokunaga, and Satoko Shiotani, and Satoko Okada, and Yoshihiko Maehara, and Takuro Niidome, and Makoto Hashizume, and Takeshi Mori, and Yoshiki Katayama
February 2008, Nano letters,
Jeong-Hun Kang, and Yoji Asami, and Masaharu Murata, and Hirotaro Kitazaki, and Noriaki Sadanaga, and Eriko Tokunaga, and Satoko Shiotani, and Satoko Okada, and Yoshihiko Maehara, and Takuro Niidome, and Makoto Hashizume, and Takeshi Mori, and Yoshiki Katayama
May 2010, Biosensors & bioelectronics,
Jeong-Hun Kang, and Yoji Asami, and Masaharu Murata, and Hirotaro Kitazaki, and Noriaki Sadanaga, and Eriko Tokunaga, and Satoko Shiotani, and Satoko Okada, and Yoshihiko Maehara, and Takuro Niidome, and Makoto Hashizume, and Takeshi Mori, and Yoshiki Katayama
February 2016, Analytical chemistry,
Jeong-Hun Kang, and Yoji Asami, and Masaharu Murata, and Hirotaro Kitazaki, and Noriaki Sadanaga, and Eriko Tokunaga, and Satoko Shiotani, and Satoko Okada, and Yoshihiko Maehara, and Takuro Niidome, and Makoto Hashizume, and Takeshi Mori, and Yoshiki Katayama
March 2022, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy,
Jeong-Hun Kang, and Yoji Asami, and Masaharu Murata, and Hirotaro Kitazaki, and Noriaki Sadanaga, and Eriko Tokunaga, and Satoko Shiotani, and Satoko Okada, and Yoshihiko Maehara, and Takuro Niidome, and Makoto Hashizume, and Takeshi Mori, and Yoshiki Katayama
March 2013, Talanta,
Copied contents to your clipboard!